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Genetic differences between individuals that affect drug action form a challenge in drug therapy. 26 
Many drugs target G protein-coupled receptors (GPCRs), and a number of receptor variants has 27 
been noted to impact drug efficacy. This, however, has never been addressed in a systematic 28 
way, and, hence, we studied real-life genetic variation of receptor function in personalized cell 29 
lines. As a showcase we studied adenosine A2A receptor (A2AR) signaling in lymphoblastoid cell 30 
lines (LCLs) derived from a family of four from the Netherlands Twin Register (NTR), using a 31 
non-invasive label-free cellular assay. The potency of a partial agonist differed significantly for 32 
one individual. Genotype comparison revealed differences in two intron SNPs including 33 
rs2236624, which has been associated with caffeine-induced sleep disorders. While further 34 
validation is needed to confirm genotype-specific effects, this set-up clearly demonstrated that 35 
LCLs are a suitable model system to study genetic influences on A2AR response in particular and 36 
GPCR responses in general. 37 
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1. Introduction 48 
 49 
The majority of therapeutic drug targets to date are within the G protein-coupled receptor 50 
(GPCR) superfamily, a class of membrane-bound proteins [1, 2]. As such, GPCRs have been 51 
widely and intensively studied for the development of new therapeutics. Amongst the most well-52 
studied members of this group are the adenosine receptors, a family comprising of 4 different 53 
subtypes: A1, A2A, A2B and A3 [3]. The various subtypes have been implied in a broad range of 54 
diseases and (patho)-physiological conditions, such as a variety of respiratory and inflammatory 55 
conditions for the A2A or cardiovascular disorders for the A1 [4]. Likewise, a wide variety of 56 
compounds selectively activating, inhibiting or modulating these receptors are available to date 57 
[3, 4]. Some of these have even been or are currently in clinical trials [3, 4]. Adenosine itself has 58 
been long approved for treatment of supraventricular tachycardia [3] and one A2AR antagonist, 59 
istradefylline, has made it to the market as adjuvant drug therapy for Parkinson’s disease in 60 
Japan [5].  61 
 62 
In the emerging era of personalized medicine, it is paramount for drug development to better 63 
understand the effects of a drug not only in the overall population, but in the individual patient as 64 
well [6]. Genetic differences between individuals can affect drug action. Accordingly, several 65 
examples linking GPCR polymorphisms to diseases and drug response variation already exist [7-66 
11], which include many commonly targeted GPCRs [11] such as purinergic [12, 13], 67 
cannabinoid [9, 10] and adenosine [14-16] receptors. Specifically for the A2A receptor, Single 68 
Nucleotide Polymorphisms (SNPs) have been associated with for instance anxiety [17, 18], 69 
caffeine intake [17], or vigilance and sleep [14]. Despite these examples of statistical association 70 
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of genotype and condition, as well as extensive mutational characterization of the adenosine 71 
receptors, little is known about the direct functional effect of receptor polymorphisms or SNPs. 72 
Therefore, an ideal set-up would be to use patient-derived material as a model system to study 73 
the influence of polymorphisms on receptor response.  74 
 75 
Lymphoblastoid cell lines (LCLs) are one of the most common choices for storing a person's 76 
genetic material [19, 20] and can be used to study GPCR function as has been shown recently 77 
[21]. For example, [22] studied the influence of a few GPCR antagonists on LCL growth. We 78 
recently published an even more direct way of measuring receptor function, including agonist 79 
and antagonist concentration-effect curves [21]. By using a newly developed, highly sensitive 80 
label-free cellular assay technology [21, 23, 24], we have shown that it is possible to measure an 81 
individual’s GPCR response in LCLs using the cannabinoid receptor 2 as example [21]. In such 82 
label-free assays one can monitor drug effects on an intact cell in real-time, rather than being 83 
limited to a static, one-molecule-detection of ligand binding or second messenger accumulation, 84 
as is usually employed in GPCR and adenosine receptor research [3, 23-25].  85 
 86 
In the current study we have applied this label-free methodology to assess personal adenosine 87 
A2A receptor function in LCLs. We characterized A2A signaling with various types of ligands 88 
including endogenous and synthetic agonists, partial agonist and antagonists, among which 89 
istradefylline. To allow conclusions about genotype in relation to receptor response, we 90 
compared responses between the individuals of a family of four from the Netherlands Twin 91 
Register [26]. This family consisted of two genetically unrelated individuals, the parents, as well 92 
as their children, which were monozygotic twins. Confirming the comparability of monozygotic 93 
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twins responses is one of the standard ways to control for genotype-unrelated effects, and 94 




2. Material and methods 97 
 98 
2.1 Chemicals and reagents 99 
Fibronectin from bovine plasma, Roswell Park Memorial Institute (RPMI) 1640 cell culture 100 
medium (25 mM HEPES and NaHCO3), NECA, adenosine and ATP were purchased from 101 
Sigma Aldrich (Zwijndrecht, The Netherlands). CGS21680, ZM241385 and CCPA were 102 
purchased from Abcam Biochemicals (Cambridge, United Kingdom), Cl-IB-MECA from Tocris 103 
Bioscience (Bristol, United Kingdom) and istradefylline from Axon Medchem (Groningen, The 104 
Netherlands). BAY60-6583 was synthesized in-house. LUF compounds were synthesized as 105 
described by [28] for LUF5448 and LUF5631, [29] for LUF5549 and LUF5550 and [30] for 106 
LUF5834. All other chemicals and reagents were of analytical grade and obtained from 107 
commercial sources, unless stated otherwise. 108 
 109 
2.2 Lymphoblastoid cell line generation 110 
The lymphoblastoid cell lines (LCLs) were generated from participants of the Netherlands Twin 111 
Register (NTR, VU, Amsterdam, The Netherlands) [26]. The LCLs were generated by the 112 
Rutgers Institute (Department of Genetics, Piscataway, NJ, USA) using a standard 113 
transformation protocol [26], according to a previous publication [21]. Peripheral B-lymphocytes 114 
were transformed with Epstein-Barr Virus (EBV) by treatment with filtered medium from a 115 
Marmoset cell line in the presence of phytohemaglutinin (PHA) during the first week of culture 116 
[19, 20, 31]. Cultures were maintained for 8-12 weeks to expand the EBV transformed 117 




2.3 Cell culture 120 
LCLs from a family of four individuals, two parents (genetically unrelated; called Parent 1 and 121 
Parent 2) and their monozygotic twin (genetically equal; called Twin 1 and Twin 2), were used 122 
for the experiments presented in this manuscript. According to culture conditions described in a 123 
previous publication [21], cryopreserved cells were thawed and resuscitated. LCLs were grown 124 
as suspension cells in RPMI 1640 (25 mM HEPES and NaHCO3) supplemented with 15% FCS, 125 
50 mg/mL streptomycin, 50 IU/mL penicillin, at 37°C and 5% CO2 and were subcultured twice a 126 
week at a ratio of 1:5 on 10 cm ø plates.  LCLs were disposed of after maximally 120 days in 127 
culture. 128 
 129 
2.4 qPCR 130 
RNA from LCLs was isolated using RNeasy Mini kit (QIAGEN, Venlo, the Netherlands). The 131 
RNA was treated with optional on column DNase digestion using DNase I (QIAGEN) and 132 
converted to cDNA using Superscript III (Invitrogen, Bleiswijk, the Netherlands). cDNA was 133 
run on custom designed 384 well qPCR plates from Lonza (Copenhagen, DK), in accordance 134 
with a previous publication [32]. These plates contained primers for 379 GPCRs as well as 3 135 
RAMPs, together with primers for Rn18s and genomic DNA (Primers are listed in Engelstoft et 136 
al. [32]). Genomic DNA sample was used as calibrator and the relative copy number was 137 
calculated as stipulated previously [32]. 138 
 139 
2.5 Label-free whole-cell analysis (xCELLigence RTCA system) 140 
2.5.1 Instrumentation principle 141 
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Cellular assays were performed using the xCELLigence RTCA system [23] in accordance with 142 
previously published protocols [21, 33]. Briefly, the real-time cell analyzer (RTCA) measures 143 
the whole-cell responses using a detection system based on electrical impedance. Impedance is 144 
generated through cell attachment to gold electrodes embedded on the bottom of the 145 
microelectronic E-plates, which changes the local ionic environment at the electrode-solution 146 
interface. Relative changes in impedance (Z) are recorded in real-time and summarized in the so-147 
called Cell Index (CI), a dimensionless parameter. The CI at any given time point is defined as 148 
(Zi-Z0) Ω /15 Ω, where Zi is the impedance at each individual time point. Z0 represents the 149 
baseline impedance in the absence of cells, which is measured prior to the start of the experiment 150 
and defined as 0. As cells adhere to the electrodes, impedance and the corresponding CI increase 151 
proportionally. Changes in cell number and degree of adhesion, as well as cellular viability and 152 
morphology are directly reflected in the impedance profile [23, 24]. Such cellular parameters are 153 
also affected upon activation of GPCR signaling, thereby allowing real-time monitoring of 154 
cellular signaling events [23].  155 
 156 
2.5.2 General protocol 157 
xCELLigence assays on LCLs were performed in accordance with a previously published 158 
protocol [21] with minor modifications. Briefly, cells were seeded onto fibronectin-coated E-159 
plates (10 μg/ml) at 80 000 cells/well. All cell counts were performed using Trypan blue staining 160 
and a BioRad TC10 automated cell counter. E-plates were placed into the recording station 161 
situated in a 37°C and 5% CO2 incubator and impedance was measured overnight. After 18 162 
hours, cells were stimulated by a GPCR ligand or vehicle control in 5 µl, unless specified 163 
otherwise. As compound solubility required addition of dimethylsulfoxide (DMSO), the final 164 
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DMSO concentration upon ligand or vehicle addition was kept at 0.25% DMSO for all wells and 165 
assays.   166 
For agonist screening purposes, cells were stimulated with agonist concentrations corresponding 167 
to 100 x Ki value for their respective receptors [4]. For the partial agonist screen, all partial 168 
agonists as well as reference agonist CGS21680 were tested at a concentration of 1 µM.  169 
Agonist concentration-response curves were generated by stimulating cells with increasing 170 
concentrations of the respective agonist. For antagonist assays, cells were pre-incubated for 30 171 
minutes with 5 μl of vehicle control or the respective antagonist at increasing concentrations. 172 
Subsequently, cells were challenged with a submaximal agonist concentration of CGS21680 that 173 
was equal to the agonist’s EC80 value (100 nM) or vehicle control. Generally, compound 174 
dilutions for concentration-response curves were generated using the digital TECAN dispenser 175 
(Tecan Group, Männedorf, Switzerland). 176 
 177 
2.6 Data analysis 178 
Data was analyzed as stipulated in the previous protocol [21]. Briefly, experimental data was 179 
obtained with RTCA Software 1.2 (Roche Applied Science). Ligand responses were normalized 180 
to Δ cell index (Δ CI) and exported to GraphPad Prism 6.0 (GraphPad Software Inc., San Diego, 181 
CA, USA) for further analysis. Vehicle control was subtracted as baseline to correct for any 182 
agonist-independent effects. Peak responses were defined as highest Δ CI (Max ∆CI) observed 183 
within 60 minutes after compound addition. When stipulated, area under the curve (AUC ∆CI) 184 
within those 60 minutes was used as an additional parameter to analyze response height. Peak 185 
values and experimental Δ CI traces were used for construction of bar graphs or concentration–186 
effect curves by nonlinear regression and calculation of IC50, EC50 and EC80 values. KI values for 187 
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antagonists were calculated using the Cheng-Prusoff equation [34] using the concentration of the 188 
agonist (CGS21680, 100 nM) and EC50 value corresponding to each cell line. 189 
All values obtained are means of at least three independent experiments performed in duplicate, 190 
unless stated otherwise. Statistical significance was determined by comparison of the means of 191 
multiple data sets by one-way ANOVA, followed by a Tukey’s post-hoc test for comparison of 192 
all columns or a Dunnett’s post-hoc test when comparing to control or reference compound.  193 
 194 
2.7 Processing of SNPs and genetic data 195 
SNP data for the four individuals was obtained from the Genomes of the Netherlands consortium 196 
(http://www.nlgenome.nl/) of which the Netherlands Twin Register is part of and analyzed in-197 




3. Results  200 
 201 
3.1 Label-free assays enable detection of adenosine A2A receptor signaling in LCLs  202 
The standard applications of label-free technologies such as the xCELLigence for GPCRs 203 
generally require adherent cell systems [23, 24, 33]. LCLs are suspension cells for which we 204 
have developed a protocol in which fibronectin coating of the plate wells allowed the LCLs to 205 
adhere [21]. With this approach we confirmed the presence or absence of adenosine receptor 206 
subtypes by testing selective agonists using LCLs of one individual as example (parent 2). These 207 
agonists included selective ligands such as CCPA for hA1AR, CGS21680 for hA2AAR, BAY60-208 
6583 for hA2BAR, Cl-IB-MECA for hA3AR and the unselective agonist NECA. To ensure full 209 
receptor occupancy, we tested the compounds at concentrations corresponding to 100x Ki value 210 
for their respective receptor [4]. An example of resulting xCELLigence traces is provided in 211 
Figure 1.  212 
 213 
Addition of the compounds induced changes in cellular morphology that were recorded in real-214 
time. Typically, agonist addition resulted in an immediate increase of impedance to a peak level 215 
which gradually decreased towards a plateau within 30 minutes. Responses were normalized to 216 
the subtype unselective agonist NECA for reference. Overall, hA2AAR selective agonist 217 
CGS21680 gave the highest response which was close to the response to NECA itself, as would 218 
be expected from the expression data which showed that hA2AAR is the highest expressed in 219 
LCLs while the other three subtypes were expressed to a much lower extent (receptor expression 220 
family mean ± SEM was hA2AAR 21.87 ± 5.41, hA1AR 1.35 ± 0.85, hA2BAR 0.88 ± 0.35 and 221 
hA3AR 0.40 ± 0.37, calculated using a normalization factor derived from all genes expressed 222 
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above genomic DNA levels, in accordance with a previous publication by Engelstoft et al. [32]). 223 
In fact, CGS21680 was the only compound whose response did not differ significantly from 224 
NECA. CCPA, the hA1AR agonist, and hA3AR agonist CL-IB-MECA gave small responses 225 
(Figure 1), most likely caused by a modest activation of A2AR at the concentrations used. While 226 
all other agonists displayed a positive impedance response, BAY60-6583 gave a small positive 227 
peak followed by a decline to a negative impedance plateau. Responses to all agonists from 228 
LCLs of a second individual, parent 1, gave comparable results in terms of conclusion of 229 
receptor subtype presence (data not shown). 230 
 231 
3.2 A2AR agonist and antagonist responses compare well between monozygotic twins and their 232 
parents  233 
Subsequently, the label-free methodology was applied to compare adenosine A2A receptor related 234 
responses between LCLs derived from the four different individuals. We characterized A2AR 235 
signaling with various types of ligands, including the endogenous agonist adenosine as well as 236 
the synthetic non-selective agonist NECA and A2AR selective agonist CGS21680. All three 237 
agonists displayed a similar shape of and height in response, both within each cell line and 238 
between individuals. An example of such a response is depicted in Figure 2A. The 239 
corresponding concentration-response curves are shown in Figure 2B-D. In a similar manner, 240 
concentration-inhibition curves for A2A antagonists ZM241385 and istradefylline were obtained. 241 
An example trace of such an agonist/antagonist experiment is in Figure 3A while the 242 
concentration-inhibition curves are represented in Figures 3B and 3C. All pEC50 and pIC50 243 
values for the LCLs of the four individuals are summarized in Table 1. From the pIC50 values we 244 
derived affinity (pKI) values for both antagonists using the Cheng-Prusoff equation. For 245 
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ZM241385 these values were 8.29 ± 0.11, 9.00 ± 0.09, 8.88 ± 0.05 and 9.08 ± 0.08 for parent 1, 246 
parent 2, twins 1 and 2. pKI values for istradefylline were 6.84 ± 0.17, 7.67 ± 0.07, 7.47 ± 0.05 247 
and 7.88 ± 0.07, respectively.  248 
 249 
3.3 A2AR partial agonist responses are measurable in LCLs 250 
Finally, we tested a number of partial agonists synthesized in house, all at a concentration of  251 
1 μM. An example trace of partial agonist and CGS21680 responses for LCLs of one individual 252 
is in Figure 4A. Some partial agonists (LUF5549 and LUF5631) displayed high efficacy in this 253 
cell system, as their maximum response almost equaled that of the full agonist CGS21680 with 254 
112 ± 9% and 95 ± 11%, respectively. LUF5448 and LUF5550 however showed robust partial 255 
agonistic behavior of 64 ± 5% and 40 ± 5% of maximal efficacy (Figure 4A). Partial agonist 256 
LUF5834 gave a different shape of response, which was marked by a negative peak followed by 257 
a negative impedance plateau, which differed significantly from any other partial agonist or 258 
reference full agonist CGS21680  (Figure 4A). Its maximum response was therefore at -17 ± 259 
8%.  260 
 261 
3.4 A2A partial agonist response differs between individuals 262 
In order to further demonstrate the sensitivity of the label-free technology combined with LCLs, 263 
one partial agonist was chosen to obtain concentration-response curves. LUF5448 was chosen as 264 
a suitable candidate as it displayed robust partial agonistic behavior with a maximum effect of 265 
approx. 50% of the reference full agonist CGS21680. An example xCELLigence trace is 266 
provided in Figure 4B while the corresponding concentration-response curves for the four 267 
individuals are summarized in Figure 4C. Interestingly, while three of the individuals gave very 268 
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comparable curves and pEC50 values, one of the parents differed significantly from all (Table 1), 269 
with an approx. tenfold higher potency (pEC50 value). LUF5448 behaved as a typical partial 270 
agonist on all cell lines with an % Max ΔCI of CGS21680 of 66 ± 7% for parent 1, 70 ± 2% for 271 
parent 2 and 67 ± 2% and 54 ± 4%  for twin 1 and 2, respectively.  272 
 273 
3.5 Genotype differences between the four individuals 274 
SNP data for the four individuals was obtained from the Genomes of the Netherlands consortium 275 
and analyzed in-house using PLINK, an open-source whole genome association analysis toolset 276 
[35, 36]. SNPs within the boundaries of the ADORA2A gene as defined by human genome 277 
overview GRCh37 were selected. Based on GRCh37 and dbSNP information 278 
(http://www.ncbi.nlm.nih.gov/SNP/), SNPs were further annotated according to position (e.g., 279 
intron, exon) and SNP type (e.g., missense, synonymous). The genotype differences of the 280 




4. Discussion 283 
 284 
It is well established that label-free technologies can be applied to investigate GPCR signaling in 285 
heterologous as well primary adherent cell systems [23, 24, 33]. For instance, the xCELLigence 286 
system has successfully been applied to study ligand effects on the cannabinoid receptor 2 (CB2) 287 
and the metabotropic glutamate receptor 1 (mGluR1) using recombinant Chinese hamster ovary 288 
(CHO) cells [37]. Similarly, A2AR signaling has been studied in HEK293hA2AAR cells using 289 
selective agonists as well as partial agonists [33]. While only such recombinant cell lines have 290 
been used to study A2AR signaling using label-free technology, A2AR  function has been studied 291 
in some endogenous cell types using other, more traditional assays [38-40]. However, studying a 292 
person’s A2AR response using a personal cell line such as the LCLs has not been possible up 293 
until now, and is therefore a translational step further towards precision medicine.  294 
Applicability of this label-free technology to LCLs is, however, not entirely straightforward due 295 
to their suspension cell nature. Nonetheless, adherence levels after coating of the wells with 296 
fibronectin were sufficient to allow monitoring of receptor responses, as was demonstrated by 297 
testing adenosine receptor ligands (Figure 1). Activation of A2AR receptors led to a typical 298 
increase in impedance often seen for GPCR ligands in LCLs. For instance, P2Y receptors 299 
(Ensembl family: ENSFM00760001715026) are abundantly present on many cell types, 300 
including LCLs [41, 42], which has made ATP a reference agonist for testing of functional LCL 301 
responses [21]. Interestingly, both adenosine receptor agonists and ATP display the same shape 302 
of response, which was also comparable to the response to cannabinoid receptor 2 (CB2) 303 
agonists as seen in an earlier publication [21]. Herein we showed that LCL densities of 50 000 304 
cells/well were sufficient for detection of a robust CB2 as well as P2Y receptor response [21]. In 305 
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the present study  seeding densities were increased to 80 000 cells/well to obtain a window 306 
sufficient for A2AR partial agonist characterization.  307 
 308 
It is well known that A2AR are expressed in immune cells, including lymphocytes and LCLs [38, 309 
43], which was confirmed in this study by both receptor expression levels in the qPCR 310 
experiments and the responses to selective adenosine receptor agonists in the label-free assay 311 
(Figure 1). The results from these tests indicated that A2AR are the only adenosine receptors 312 
highly expressed in LCLs. This was further confirmed by the comparability of the responses of 313 
all three full agonists tested in this paper. The endogenous ligand adenosine as well as subtype 314 
unselective NECA and A2AR selective agonist CGS21680 had comparable responses (Figure 2) 315 
suggesting these were all mediated through the A2AR. Similarly, antagonist responses were also 316 
measurable for all four different individuals (Figure 3), strengthening the conclusion that 317 
responses are mediated through A2AR only. 318 
 319 
While it is straightforward to confirm that an impedance response is a specific receptor-mediated 320 
effect with recombinant cell lines, namely by simply using the untransfected parental cell line as 321 
negative control [33, 37], this is not possible in cell lines with endogenous receptor expression. 322 
Therefore, for LCLs the most reliable way is to confirm overall receptor pharmacology with 323 
receptor subtype-selective agonists and antagonists. By showing that the A2AR selective 324 
ZM241385 and istradefylline competed with and blocked the signal of the A2AR selective 325 
CGS21680 (Figure 3), we confirmed that the impedance effects indeed originate from an A2AR 326 




Overall, agonist pEC50 values for agonists were within a log unit from previously reported 329 
literature values obtained with standard functional assays on heterologous cell lines (Table 1). 330 
For instance, adenosine itself is within that range as it has been reported with an EC50 value of 331 
310 nM in a cAMP assay on hA2AAR [44]. For the antagonists, the calculated pKI values of 332 
ZM241385 and istradefylline were also within the range of previously published values. This 333 
calculation corrects for the fact that the same concentration of agonist was used during the assay, 334 
corresponding to the EC80 of CGS21680, while the efficacy of this agonist differed slightly 335 
between cell lines.  336 
 337 
Following this characterization of full agonists and antagonists to verify the presence and 338 
functional relevance of A2AR, a number of partial agonists were tested to demonstrate the 339 
sensitivity of the system. The set-up was well able to measure partial agonist effects on LCLs, 340 
quite comparable to our previous study on HEK293hA2AAR cells (20). Interestingly, while most 341 
agonists induced an increase in impedance with a single peak in LCLs, there were two agonists 342 
which gave rise to a different shape of response. Both BAY60-6583 and the partial agonist 343 
LUF5834 responses were marked by a small peak followed by a negative impedance plateau, 344 
rather than one positive peak (Figure 1 and 4). Interestingly, both BAY60-6583 and LUF5834 345 
belong to a structurally distinct class of non-ribose agonists, as opposed to all other agonists 346 
tested in this paper. Hence, it seems that non-ribose agonists, while equally able to activate the 347 
hA2AAR, give rise to a different cellular response than the more common ribose-containing 348 
agonists. This was not observed in the heterologous HEK293hA2AAR cell line where partial 349 
agonist LUF5834 had been tested previously [33], which highlights the differences of using an 350 
unmodified human cell line when characterizing compound effects. In fact, efficacies and 351 
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signaling of ligands can differ under artificial or heterologous conditions due to a number of 352 
factors [23, 45]. Receptor overexpression, differences in intracellular metabolic conditions as 353 
well as products from other genes could modify cellular responses. Unfortunately, most studies 354 
of receptor function involve artificially expressed receptors in heterologous cell systems, such as 355 
CHO or HEK cells [3, 33]. While useful for high-throughput screening and fundamental 356 
research, such systems are far from the real-life situation in an individual. To move further 357 
towards the physiological situation, it is essential to study receptor function in a more 358 
endogenous setting such as LCLs. This is especially true when attempting to understand how 359 
polymorphisms may functionally affect the receptor and therefore the drug response of an 360 
individual.  361 
 362 
Employing the LCLs, we investigated genotype effects on receptor response by comparing the 363 
effects of various types of A2A ligands between the individuals of a family of four from the 364 
Netherlands Twin Register, which consisted of two genetically unrelated individuals, the parents, 365 
and their children, which were monozygotic twins. Overall, the results were comparable between 366 
all individuals. Analyzing and confirming the comparability of results obtained in monozygotic 367 
twins is one of the standard ways in genetic studies to control for genotype-unrelated effects, and 368 
assess a system’s suitability for genetic studies [26, 27]. As expected, the twins did not differ 369 
significantly from each other, with exception of their pEC50 values for NECA (p<0.05; Table 1). 370 
Interestingly, NECA was also the only ligand for which all individuals differed significantly in 371 
their pEC50 values. As monozygotic twins are genetically identical, these differences could not 372 
be related to genetic effects and therefore precluded any further conclusion about differences 373 
between the parents. However, parent 1 showed significant differences on two occasions, when 374 
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all other three individuals, including the monozygotic twins, were comparable. This was the case 375 
with istradefylline as well as with the partial agonist LUF5448. While with istradefylline the 376 
difference was rather marginal within half a log unit, the potency shift (approx. tenfold higher) 377 
for LUF5448 was much more pronounced for parent 1. Partial agonists are deemed more 378 
sensitive to system-related differences in receptor function, for instance in receptor expression or 379 
downstream coupling, than full agonists or antagonists [29]. Therefore, the difference in potency 380 
possibly reflects subtle changes introduced by the genetic differences between individuals. While 381 
none of the four individuals had non-synonymous SNPs in the ADORA2A gene (Table 2), there 382 
were some heterozygous differences present in non-coding SNPs. Two SNP differences were in 383 
line with the pEC50 and pIC50 changes, namely in which only parent 1 differed while parent 2 384 
and the twins showed the same genotype and response. These were rs34999116 where parent 1 is 385 
heterozygote for the minor allele and rs2236624 where parent 1 is homozygote for the minor 386 
allele. Interestingly, the C-allele of rs2236624, which is located in intron 4 of the ADORA2A 387 
gene, has been associated with vigilance and sleep, while the CC genotype has been associated 388 
with anxiety in autism patients [2, 15, 16]. The TT genotype has been associated with 389 
pharmacotherapy-related toxicities in acute lymphoblastic leukemia [46]. Several studies have 390 
proposed a subtle effect on receptor expression as possible mechanism, as this intron SNP has 391 
intermediate regulatory potential [16, 46]. As we did not observe significant differences  in 392 
receptor mRNA levels in our qPCR experiments, this regulation may affect the subsequent 393 
translation. Changes in receptor expression may affect G protein coupling efficiency, for which a 394 




Although this genetic variation does not provide causal evidence that response differences as 397 
observed in the LCLs from these individuals are directly related to these SNPs, the experimental 398 
results show that the chosen methodology and set-up are capable of picking up individual 399 
differences in receptor signaling for the A2AR. Although A2AR function has been studied in 400 
endogenous cell types [38-40], we made a further step towards both physiological relevant 401 
conditions and personalized medicine by enabling the study of a person’s A2AR response using a 402 
combination of LCLs from a family of four from the NTR and a non-invasive label-free cellular 403 
assay.  404 
 405 
It is increasingly recognized that genetic differences between individuals form a large challenge 406 
in drug therapy indeed. In our study of real-life genetic variation of A2AR signaling, we found 407 
that partial agonist potency differed significantly for one individual with genotype differences in 408 
two intron SNPs, one of which has previously been associated with caffeine-induced sleep 409 
disorders. While further validation is needed to confirm genotype-specific effects, this set-up 410 
clearly demonstrated that LCLs are a suitable model system to study genetic influences on A2AR 411 
and GPCR responses in general. LCLs express a wide range of other ‘drugable’ GPCRs, besides 412 
the A2AR, CB2 and P2Y receptors investigated in this and earlier studies [21, 43]. Therefore, 413 
screening receptor responses in LCLs may help to provide the mechanistic link between 414 
polymorphisms of various GPCRs and the individual variation in drug response. 415 
 416 
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Table 1: Overview of the pEC50 and pIC50 values of Adenosine, NECA, CGS21680, 609 
ZM241385, istradefylline and LUF5448 for the tested individuals’ LCLs. Data represents the 610 
means of at least three separate experiments performed in duplicate. Statistical analysis was 611 
performed with one-way ANOVA with Tukey post-hoc test. Asterisks highlight statistical 612 
differences to the other individuals (P1 = parent 1; P2 = parent 2; T1 = Twin 1; T2 = twin 2). * 613 
p<0.05, ** p<0.01,*** p<0.001. 614 
Ligand 
pEC50 / pIC50 (M) 











8.60 ± 0.02 [33]  
7.59 ± 0.33 [47] 
7.54 ± 0.07 
*** P2 
** T2 
8.06 ± 0.04 
*** P1 
** T1 
7.68 ± 0.04 
** P2 
* T2 






8.42 ± 0.05 [33]  
8.18 ± 0.36 [39] 


















6.45 ± 0.04 
* P1 
 
6.66 ± 0.02 
** P1 
 





8.62 ± 0.19  
[33] 
8.69 ± 0.11 
** all  
7.60 ± 0.11 
** P1 
7.69 ± 0.08  
** P1 





Table 2: SNP genotype differences within the ADORA2A gene between the four individuals 615 
included in this study. The heterozygous differences of parent 1 to the other individuals are 616 







Parent 1 Parent 2 Twins 
rs34999116 T C C C C C 
rs5751869 A G A G G G 
rs5760410 A G A G G G 
rs5751870 T G T G G G 
rs5751871 T G T G G G 
rs9624470 A G A G G G 
rs11704959 A C C C A C 
rs2298383 T C T C C C 
rs3761420 A G A G G G 
rs3761422 C T C T T T 
rs2267076 C T C T T T 
rs11704811 T C C C T C 
rs17650801 G G A G G G 
rs4822489 G T G T T T 
rs2236624 C C T C T C 






Figure 1: Adenosine receptor agonist screen. Cells were seeded onto fibronectin-coated wells 625 
(10 µg/ml) at 80 000 cells/well. After 18 hours of growth, cells were stimulated with AR ligands 626 
at concentrations corresponding to 100 x Ki value for their respective receptor [4]. CCPA (83 627 
nM) for hA1AR at, CGS21680 (2.7 µM) for hA2AAR, BAY60-6583 (36 µM) for hA2BAR and 628 
Cl-IB-MECA (140 nM) for hA3AR were compared to the unselective hAR agonist NECA. 629 
Unselective NECA was tested a concentration of 14 µM which is at least 100 x KI or more for all 630 
ARs. Representative xCELLigence traces of a baseline-corrected ligand response are given of 631 
one individual (parent 2), where time point 0 represents the time of ligand addition. Data are 632 
from at least 3 separate experiments performed in duplicate. Statistical difference of compound 633 
responses to NECA were analyzed using one-way ANOVA with Dunnett's post-hoc test. * 634 
p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001. Response heights normalized to NECA (100 ± 635 
1%) were for CCPA: 35 ± 5% ***, CGS21680: 67 ± 11%, BAY60-6583: -40 ± 14% **** and 636 





Figure 2: Characterization of full agonist responses in LCLs from a family of four from the 640 
NTR. The family consists of two genetically unrelated individuals, parent 1 and 2, and their 641 
children which are a monozygotic twin (twin 1 and twin 2). Cell lines were stimulated with 642 
endogenous agonist adenosine [1 nM - 100 μM], synthetic agonists NECA or CGS21680 [100 643 
pM - 1 μM] 18h after seeding (80 000 cells/well). Representative example of a baseline-644 
corrected concentration-dependent CGS21680 response (A). Concentration-response curves for 645 
CGS21680 (B), NECA (C) and adenosine (D) were derived from peak Δ cell index (Δ CI) within 646 
60 minutes after agonist addition (see Methods). Data in B-D represents the means of at least 647 





Figure 3: Characterization of A2AR antagonist responses in LCLs from a family of four 651 
from the NTR. The family consists of two genetically unrelated individuals, parent 1 and 2, and 652 
their children which are a monozygotic twin (twin 1 and twin 2). For antagonist curves, cell lines 653 
were pre-incubated for 30 minutes with increasing concentrations of ZM241385 [10 pM - 10 654 
μM] before stimulation with CGS21680 [EC80: 100 nM] 18h after seeding (80 000 cells/well). 655 
Representative example of a baseline-corrected concentration-dependent response to ZM241385 656 
(A). Concentration-response curves for ZM241385 (B) and istradefylline (C) were derived from 657 
peak Δ cell index (Δ CI) values within 60 minutes after agonist addition. Data in B-C represents 658 





Figure 4: A2AR partial agonist responses in LCLs. Cells were stimulated 18h after seeding  662 
(80 000 cells/well) with A2AR partial agonists as well as full agonist CGS21680 [all at 1 μM] for 663 
reference. (A) Representative example of a baseline-corrected response is given from one 664 
individual (parent 2). Maximal responses of partial agonists compared to CGS21680 were 112 ± 665 
9% for LUF5549,  95 ± 11% for LUF5631,  64 ± 5%* for LUF5448, 40 ± 5%*** for LUF5550 666 
and -17 ± 8%**** for LUF5834. Statistical differences from CGS21680 were assessed with a 667 
one-way ANOVA with Dunnett’s post-hoc test. * p<0.05, ** p<0.01, *** p<0.001, **** 668 
p<0.0001. (B) Representative example of a baseline-corrected response of A2AR partial agonist 669 
LUF5448 [10 pM - 1 μM]  for one individual (parent 2). (C) Concentration-response curves for 670 
36 
 
all four individuals were derived from peak Δ cell index (Δ CI) within 60 minutes after agonist 671 
addition, normalized to CGS21680 as reference. Data represents at least three separate 672 
experiments performed in duplicate.  673 
